EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Can Galectin-3 Be a Novel Biomarker in Chronic Lymphocytic Leukemia?

Justyna Woś, Agata Szymańska, Natalia Lehman iD, Sylwia Chocholska iD, Michał Zarobkiewicz iD, Piotr Pożarowski iD, Agnieszka Bojarska-Junak iD

Cells · 2023

DOI: 10.3390/cells13010030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Justyna Woś und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Medical University of Lublin, 20-093 Lublin, Poland. Hauptthemen laut MEDLINE: Galectin 3, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lublin, Medical University of Lublin, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Galectin-3’s (Gal-3) effect on the pathogenesis of chronic lymphocytic leukemia (CLL) has not yet been extensively studied. The present study aims to analyze the potential role of Gal-3 as a prognostic biomarker in CLL patients. The Gal-3 expression was evaluated in CLL cells with RT-qPCR and flow cytometry. Due to the unclear clinical significance of soluble Gal-3 in CLL, our goal was also to assess the prognostic value of Gal-3 plasma level. Because cell survival is significantly affected by the interaction between Gal-3 and proteins such as Bcl-2, the results of Gal-3 expression analysis were also compared with the expression of Bcl-2. The results were analyzed for known prognostic factors, clinical data, and endpoints such as time to first treatment and overall survival time. Our research confirmed that Gal-3 is detected in and on CLL cells. However, using Gal-3 as a potential biomarker in CLL is challenging due to the significant heterogeneity in its expression in CLL cells. Moreover, our results revealed that Gal-3 mRNA expression in leukemic B cells is associated with the expression of proliferation markers (Ki-67 and PCNA) as well as anti-apoptotic protein Bcl-2 and can play an important role in supporting CLL cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Galectin 3Leukemia, Lymphocytic, Chronic, B-CellHumansB-LymphocytesBiomarkersProto-Oncogene Proteins c-bcl-2Blood ProteinsGalectins

Stichwörter der Autor:innen

CLLGalectin-3prognostic markerstumor microenvironment

Substanzen

BiomarkersGalectin 3Proto-Oncogene Proteins c-bcl-2LGALS3 protein, humanBlood ProteinsGalectins

Autor:innen und Institutionen

  • Department of Clinical Immunology, Medical University of Lublin, 20-093 Lublin, Poland.
  • Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-080 Lublin, Poland.

ORCID-Profile: Natalia Lehman, Sylwia Chocholska, Michał Zarobkiewicz, Piotr Pożarowski, Agnieszka Bojarska-Junak

Förderung

  • Medical University of Lublin
  • Medical University of Lublin, Poland

Zitieren

APA

Woś, J., Szymańska, A., Lehman, N., Chocholska, S., Zarobkiewicz, M., Pożarowski, P., & Bojarska-Junak, A. (2023). Can Galectin-3 Be a Novel Biomarker in Chronic Lymphocytic Leukemia?. Cells. https://doi.org/10.3390/cells13010030

Vancouver

Woś J, Szymańska A, Lehman N, Chocholska S, Zarobkiewicz M, Pożarowski P, et al. Can Galectin-3 Be a Novel Biomarker in Chronic Lymphocytic Leukemia?. Cells. 2023. doi:10.3390/cells13010030

BibTeX
@article{Wo2023,
  author = {Woś, Justyna and Szymańska, Agata and Lehman, Natalia and Chocholska, Sylwia and Zarobkiewicz, Michał and Pożarowski, Piotr and Bojarska-Junak, Agnieszka},
  title = {Can Galectin-3 Be a Novel Biomarker in Chronic Lymphocytic Leukemia?},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells13010030}
}
Kostenlos starten →